{
  "zip": "L5L 1J9",
  "sector": "Healthcare",
  "fullTimeEmployees": 11,
  "longBusinessSummary": "Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. In addition, the company provides TriVair technology platform that offer applications for pulmonary and nasal pharmaceutical medications. Acerus Pharmaceuticals Corporation sells products through its salesforce in the United States; and through a network of distributors internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.",
  "city": "Mississauga",
  "phone": "416 679 0771",
  "state": "ON",
  "country": "Canada",
  "companyOfficers": [],
  "website": "http://www.aceruspharma.com",
  "maxAge": 1,
  "address1": "2486 Dunwin Drive",
  "industry": "Drug Manufacturersâ€”Specialty & Generic",
  "previousClose": 0.031,
  "regularMarketOpen": 0.0358,
  "twoHundredDayAverage": 0.036906473,
  "trailingAnnualDividendYield": null,
  "payoutRatio": 0,
  "volume24Hr": null,
  "regularMarketDayHigh": 0.031,
  "navPrice": null,
  "averageDailyVolume10Day": 30325,
  "totalAssets": null,
  "regularMarketPreviousClose": 0.031,
  "fiftyDayAverage": 0.031212121,
  "trailingAnnualDividendRate": null,
  "open": 0.0358,
  "averageVolume10days": 30325,
  "expireDate": null,
  "yield": null,
  "algorithm": null,
  "dividendRate": null,
  "exDividendDate": null,
  "beta": 0.997359,
  "circulatingSupply": null,
  "startDate": null,
  "regularMarketDayLow": 0.031,
  "priceHint": 4,
  "currency": "USD",
  "regularMarketVolume": 20579,
  "lastMarket": null,
  "maxSupply": null,
  "openInterest": null,
  "marketCap": 47665288,
  "volumeAllCurrencies": null,
  "strikePrice": null,
  "averageVolume": 25004,
  "priceToSalesTrailing12Months": 35.892536,
  "dayLow": 0.031,
  "ask": null,
  "ytdReturn": null,
  "askSize": null,
  "volume": 20579,
  "fiftyTwoWeekHigh": 0.09,
  "forwardPE": null,
  "fromCurrency": null,
  "fiveYearAvgDividendYield": null,
  "fiftyTwoWeekLow": 0.02,
  "bid": null,
  "tradeable": false,
  "dividendYield": null,
  "bidSize": null,
  "dayHigh": 0.031,
  "exchange": "PNK",
  "shortName": "ACERUS PHARMACEUTICALS CORP",
  "longName": "Acerus Pharmaceuticals Corporation",
  "exchangeTimezoneName": "America/New_York",
  "exchangeTimezoneShortName": "EST",
  "isEsgPopulated": false,
  "gmtOffSetMilliseconds": "-18000000",
  "underlyingSymbol": null,
  "quoteType": "EQUITY",
  "symbol": "ASPCF",
  "underlyingExchangeSymbol": null,
  "headSymbol": null,
  "messageBoardId": "finmb_97989769",
  "uuid": "a3aa1001-90e0-3bf2-8317-45cd48df7c78",
  "market": "us_market",
  "annualHoldingsTurnover": null,
  "enterpriseToRevenue": 26.56,
  "beta3Year": null,
  "profitMargins": 0,
  "enterpriseToEbitda": -1.908,
  "52WeekChange": null,
  "morningStarRiskRating": null,
  "forwardEps": null,
  "revenueQuarterlyGrowth": null,
  "sharesOutstanding": 1537590016,
  "fundInceptionDate": null,
  "annualReportExpenseRatio": null,
  "bookValue": 0,
  "sharesShort": null,
  "sharesPercentSharesOut": null,
  "fundFamily": null,
  "lastFiscalYearEnd": 1577750400,
  "heldPercentInstitutions": 0,
  "netIncomeToCommon": -21204000,
  "trailingEps": -0.029,
  "lastDividendValue": null,
  "SandP52WeekChange": null,
  "priceToBook": null,
  "heldPercentInsiders": 0.91635,
  "nextFiscalYearEnd": 1640908800,
  "mostRecentQuarter": 1601424000,
  "shortRatio": null,
  "sharesShortPreviousMonthDate": null,
  "floatShares": 87177502,
  "enterpriseValue": 35271632,
  "threeYearAverageReturn": null,
  "lastSplitDate": null,
  "lastSplitFactor": null,
  "legalType": null,
  "morningStarOverallRating": null,
  "earningsQuarterlyGrowth": null,
  "dateShortInterest": null,
  "pegRatio": null,
  "lastCapGain": null,
  "shortPercentOfFloat": null,
  "sharesShortPriorMonth": null,
  "category": null,
  "fiveYearAverageReturn": null,
  "regularMarketPrice": 0.0358,
  "logo_url": "https://logo.clearbit.com/aceruspharma.com"
}